Scholarlink

Background <p>Sustainability in healthcare, particularly Nuclear Medicine, is essential, especially in managing radioactive materials. Traditional centralized production of Fluorine-18 tracers for PET imaging faces challenges like transport logistics, decay losses and supply chain vulnerabilities. Decentralized production with radionuclide generators, such as the Germanium-68/Gallium-68 (<sup>68</sup>Ge/<sup>68</sup>Ga) generator, offers on-demand isotope production, improving accessibility and precision imaging. This study evaluates the long-term performance (8&#xa0;years) of <sup>68</sup>Ga-based radiopharmaceutical production in a Nuclear Medicine Division, focusing on efficiency, sustainability, and cost.</p> Results <p>Between 2016 and 2024, 416 batches of <sup>68</sup>GaCl₃ and 2455 batches of <sup>68</sup>Ga-based radiopharmaceuticals were produced. Data from systematic quality controls on generator eluates and tracers, such as <sup>68</sup>Ga-PSMA (1800 batches) and <sup>68</sup>Ga-DOTATOC (610 batches), were evaluated. All <sup>68</sup>GaCl₃ eluates met Ph. Eur. specifications, with negligible <sup>68</sup>Ge breakthrough (mean 0.0000068%) and consistently high radiochemical purity (100%). Radiopharmaceuticals showed stable quality over time, with &gt; 98% purity for <sup>68</sup>Ga-DOTATOC and &gt; 99% for <sup>68</sup>Ga-PSMA. Generators performance remained reliable, with an average elution yield of 74.8% (range 63.4–84.7%) and up to 466 elutions/year reached in 2024 without quality degradation. The correlation between estimated and measured end-of-synthesis activities was strong (R<sup>2</sup> ≈ 1), supporting accurate production planning. Clinical PET scans increased over sixfold, from 144 in 2016 to 920 in 2025. The high-sensitivity PET/CT system helped reduce injected activity and acquisition time, improving throughput and sustaining growth. The clinical-to-production ratio progressively decreased from 1 (1 batch/exam) to 0.42 for <sup>68</sup>Ga-PSMA (range 0.37–0.51) and 0.49 for <sup>68</sup>Ga-DOTATOC (range 0.40–0.60), indicating better batch utilization and workflow efficiency. Cost analysis showed module-based synthesis was most efficient during high-yield phases of the generators, while kit-based approaches were more cost-effective at later stages. Supply logistics of precursors and reagents has shown to be more sustainable for in-house production of radiopharmaceuticals compared to the purchased ones from external facilities.</p> Conclusions <p>The <sup>68</sup>Ge/<sup>68</sup>Ga generator supports reliable, sustainable, and cost-effective radiopharmaceutical production, enhancing efficiency and clinical capacity in PET imaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The 68Ge/68Ga generator for enhancing productivity and reducing costs in nuclear medicine: experience from a university hospital

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Alessandra Guercio,
  • Tess Martin,
  • Silvia Migliari,
  • Anna Gagliardi,
  • Maura Scarlattei,
  • Giorgio Baldari,
  • Nicolas Martelli,
  • Livia Ruffini

摘要

Background

Sustainability in healthcare, particularly Nuclear Medicine, is essential, especially in managing radioactive materials. Traditional centralized production of Fluorine-18 tracers for PET imaging faces challenges like transport logistics, decay losses and supply chain vulnerabilities. Decentralized production with radionuclide generators, such as the Germanium-68/Gallium-68 (68Ge/68Ga) generator, offers on-demand isotope production, improving accessibility and precision imaging. This study evaluates the long-term performance (8 years) of 68Ga-based radiopharmaceutical production in a Nuclear Medicine Division, focusing on efficiency, sustainability, and cost.

Results

Between 2016 and 2024, 416 batches of 68GaCl₃ and 2455 batches of 68Ga-based radiopharmaceuticals were produced. Data from systematic quality controls on generator eluates and tracers, such as 68Ga-PSMA (1800 batches) and 68Ga-DOTATOC (610 batches), were evaluated. All 68GaCl₃ eluates met Ph. Eur. specifications, with negligible 68Ge breakthrough (mean 0.0000068%) and consistently high radiochemical purity (100%). Radiopharmaceuticals showed stable quality over time, with > 98% purity for 68Ga-DOTATOC and > 99% for 68Ga-PSMA. Generators performance remained reliable, with an average elution yield of 74.8% (range 63.4–84.7%) and up to 466 elutions/year reached in 2024 without quality degradation. The correlation between estimated and measured end-of-synthesis activities was strong (R2 ≈ 1), supporting accurate production planning. Clinical PET scans increased over sixfold, from 144 in 2016 to 920 in 2025. The high-sensitivity PET/CT system helped reduce injected activity and acquisition time, improving throughput and sustaining growth. The clinical-to-production ratio progressively decreased from 1 (1 batch/exam) to 0.42 for 68Ga-PSMA (range 0.37–0.51) and 0.49 for 68Ga-DOTATOC (range 0.40–0.60), indicating better batch utilization and workflow efficiency. Cost analysis showed module-based synthesis was most efficient during high-yield phases of the generators, while kit-based approaches were more cost-effective at later stages. Supply logistics of precursors and reagents has shown to be more sustainable for in-house production of radiopharmaceuticals compared to the purchased ones from external facilities.

Conclusions

The 68Ge/68Ga generator supports reliable, sustainable, and cost-effective radiopharmaceutical production, enhancing efficiency and clinical capacity in PET imaging.